-
1
-
-
84960366855
-
Development of immuno-oncology drugs-from CTLA4 to PD1 to the next generations
-
Hoos, A. Development of immuno-oncology drugs-from CTLA4 to PD1 to the next generations. Nat. Rev. Drug Discov. 15, 235-247 (2016).
-
(2016)
Nat. Rev. Drug Discov.
, vol.15
, pp. 235-247
-
-
Hoos, A.1
-
2
-
-
84964290544
-
Nivolumab in resected and unresectable metastatic melanoma: Characteristics of immune-related adverse events and association with outcomes
-
Freeman-Keller, M. et al. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin. Cancer Res. 22, 886-894 (2016).
-
(2016)
Clin. Cancer Res.
, vol.22
, pp. 886-894
-
-
Freeman-Keller, M.1
-
3
-
-
73149092567
-
Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria
-
Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
-
(2009)
Clin. Cancer Res.
, vol.15
, pp. 7412-7420
-
-
Wolchok, J.D.1
-
4
-
-
0025963233
-
Graft-versus-host disease
-
Ferrara, J. L. & Deeg, H. J. Graft-versus-host disease. N. Engl. J. Med. 324, 667-674 (1991).
-
(1991)
N. Engl. J. Med.
, vol.324
, pp. 667-674
-
-
Ferrara, J.L.1
Deeg, H.J.2
-
5
-
-
84899873585
-
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution
-
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J. & Fagin, J. A. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr. Relat. Cancer 21, 371-381 (2014).
-
(2014)
Endocr. Relat. Cancer
, vol.21
, pp. 371-381
-
-
Ryder, M.1
Callahan, M.2
Postow, M.A.3
Wolchok, J.4
Fagin, J.A.5
-
6
-
-
77951891703
-
Prediction and pathogenesis in type 1 diabetes
-
Ziegler, A. G. & Nepom, G. T. Prediction and pathogenesis in type 1 diabetes. Immunity 32, 468-478 (2010).
-
(2010)
Immunity
, vol.32
, pp. 468-478
-
-
Ziegler, A.G.1
Nepom, G.T.2
-
7
-
-
0031786356
-
Tumor-specific killer cells in paraneoplastic cerebellar degeneration
-
Albert, M. L. et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nat. Med. 4, 1321-1324 (1998).
-
(1998)
Nat. Med.
, vol.4
, pp. 1321-1324
-
-
Albert, M.L.1
-
8
-
-
0033537356
-
Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma
-
Maddison, P., Newsom-Davis, J., Mills, K. R. & Souhami, R. L. Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet 353, 117-118 (1999).
-
(1999)
Lancet
, vol.353
, pp. 117-118
-
-
Maddison, P.1
Newsom-Davis, J.2
Mills, K.R.3
Souhami, R.L.4
-
9
-
-
79960657821
-
Autoimmunity associated with immunotherapy of cancer
-
Amos, S. M. et al. Autoimmunity associated with immunotherapy of cancer. Blood 118, 499-509 (2011).
-
(2011)
Blood
, vol.118
, pp. 499-509
-
-
Amos, S.M.1
-
10
-
-
84953309212
-
Immune-related adverse events with immune checkpoint blockade: A comprehensive review
-
Michot, J. M. et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139-148 (2016).
-
(2016)
Eur. J. Cancer
, vol.54
, pp. 139-148
-
-
Michot, J.M.1
-
11
-
-
79954551032
-
Mechanisms of tolerance
-
Bluestone, J. A. Mechanisms of tolerance. Immunol. Rev. 241, 5-19 (2011).
-
(2011)
Immunol. Rev.
, vol.241
, pp. 5-19
-
-
Bluestone, J.A.1
-
12
-
-
79954463242
-
Control of central and peripheral tolerance by Aire
-
Metzger, T. C. & Anderson, M. S. Control of central and peripheral tolerance by Aire. Immunol. Rev. 241, 89-103 (2011).
-
(2011)
Immunol. Rev.
, vol.241
, pp. 89-103
-
-
Metzger, T.C.1
Anderson, M.S.2
-
13
-
-
84874745221
-
Aire-dependent thymic development of tumor-associated regulatory T cells
-
Malchow, S. et al. Aire-dependent thymic development of tumor-associated regulatory T cells. Science 339, 1219-1224 (2013).
-
(2013)
Science
, vol.339
, pp. 1219-1224
-
-
Malchow, S.1
-
14
-
-
0036360019
-
The enemy within: Keeping self-reactive T cells at bay in the periphery
-
Walker, L. S. & Abbas, A. K. The enemy within: keeping self-reactive T cells at bay in the periphery. Nat. Rev. Immunol. 2, 11-19 (2002).
-
(2002)
Nat. Rev. Immunol.
, vol.2
, pp. 11-19
-
-
Walker, L.S.1
Abbas, A.K.2
-
15
-
-
79954486763
-
Regulatory T cells and Foxp3
-
Rudensky, A. Y. Regulatory T cells and Foxp3. Immunol. Rev. 241, 260-268 (2011).
-
(2011)
Immunol. Rev.
, vol.241
, pp. 260-268
-
-
Rudensky, A.Y.1
-
16
-
-
84880145306
-
Database of T cell-defined human tumor antigens: The 2013 update
-
Vigneron, N., Stroobant, V., Van den Eynde, B. J. & van der Bruggen, P. Database of T cell-defined human tumor antigens: the 2013 update. Cancer Immun. 13, 15 (2013).
-
(2013)
Cancer Immun.
, vol.13
, pp. 15
-
-
Vigneron, N.1
Stroobant, V.2
Van Den Eynde, B.J.3
Van Der Bruggen, P.4
-
17
-
-
84859416933
-
Regulatory T cells: Mechanisms of differentiation and function
-
Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531-564 (2012).
-
(2012)
Annu. Rev. Immunol.
, vol.30
, pp. 531-564
-
-
Josefowicz, S.Z.1
Lu, L.F.2
Rudensky, A.Y.3
-
18
-
-
84961218930
-
AIRE expands: New roles in immune tolerance and beyond
-
Anderson, M. S. & Su, M. A. AIRE expands: new roles in immune tolerance and beyond. Nat. Rev. Immunol. 16, 247-258 (2016).
-
(2016)
Nat. Rev. Immunol.
, vol.16
, pp. 247-258
-
-
Anderson, M.S.1
Su, M.A.2
-
19
-
-
84862127502
-
Immunosuppression in the tumor microenvironment: Where are we standing?
-
Umansky, V. Immunosuppression in the tumor microenvironment: where are we standing? Semin. Cancer Biol. 22, 273-274 (2012).
-
(2012)
Semin. Cancer Biol.
, vol.22
, pp. 273-274
-
-
Umansky, V.1
-
20
-
-
84891876304
-
Regulatory T cell subsets in human cancer: Are they regulating for or against tumor progression?
-
Whiteside, T. L. Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? Cancer Immunol. Immunother. 63, 67-72 (2014).
-
(2014)
Cancer Immunol. Immunother.
, vol.63
, pp. 67-72
-
-
Whiteside, T.L.1
-
21
-
-
84922475661
-
CCR4 and its ligands: From bench to bedside
-
Yoshie, O. & Matsushima, K. CCR4 and its ligands: from bench to bedside. Int. Immunol. 27, 11-20 (2015).
-
(2015)
Int. Immunol.
, vol.27
, pp. 11-20
-
-
Yoshie, O.1
Matsushima, K.2
-
22
-
-
79955529454
-
Trans-endocytosis of CD80 and CD86: A molecular basis for the cell-extrinsic function of CTLA-4
-
Qureshi, O. S. et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332, 600-603 (2011).
-
(2011)
Science
, vol.332
, pp. 600-603
-
-
Qureshi, O.S.1
-
23
-
-
0346119234
-
Modulation of tryptophan catabolism by regulatory T cells
-
Fallarino, F. et al. Modulation of tryptophan catabolism by regulatory T cells. Nat. Immunol. 4, 1206-1212 (2003).
-
(2003)
Nat. Immunol.
, vol.4
, pp. 1206-1212
-
-
Fallarino, F.1
-
24
-
-
42649125225
-
PD-1 and its ligands in tolerance and immunity
-
Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26, 677-704 (2008).
-
(2008)
Annu. Rev. Immunol.
, vol.26
, pp. 677-704
-
-
Keir, M.E.1
Butte, M.J.2
Freeman, G.J.3
Sharpe, A.H.4
-
25
-
-
79960906880
-
Role of PD-1 in regulating T-cell immunity
-
Jin, H. T., Ahmed, R. & Okazaki, T. Role of PD-1 in regulating T-cell immunity. Curr. Top. Microbiol. Immunol. 350, 17-37 (2011).
-
(2011)
Curr. Top. Microbiol. Immunol.
, vol.350
, pp. 17-37
-
-
Jin, H.T.1
Ahmed, R.2
Okazaki, T.3
-
26
-
-
0142149029
-
Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells
-
Blank, C. et al. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J. Immunol. 171, 4574-4581 (2003).
-
(2003)
J. Immunol.
, vol.171
, pp. 4574-4581
-
-
Blank, C.1
-
27
-
-
84959292227
-
IDO in the tumor microenvironment: Inflammation, counter-regulation, and tolerance
-
Munn, D. H. & Mellor, A. L. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 37, 193-207 (2016).
-
(2016)
Trends Immunol.
, vol.37
, pp. 193-207
-
-
Munn, D.H.1
Mellor, A.L.2
-
28
-
-
84937605130
-
Toxicities of immunotherapy for the practitioner
-
Weber, J. S., Yang, J. C., Atkins, M. B. & Disis, M. L. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol. 33, 2092-2099 (2015).
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 2092-2099
-
-
Weber, J.S.1
Yang, J.C.2
Atkins, M.B.3
Disis, M.L.4
-
29
-
-
84904097189
-
Current concepts in the diagnosis and management of cytokine release syndrome
-
Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188-195 (2014).
-
(2014)
Blood
, vol.124
, pp. 188-195
-
-
Lee, D.W.1
-
30
-
-
84899071058
-
Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody
-
Iwama, S. et al. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230ra45 (2014).
-
(2014)
Sci. Transl. Med.
, vol.6
, pp. 230ra45
-
-
Iwama, S.1
-
31
-
-
20044395957
-
Autoimmunity in a phase i trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma
-
Sanderson, K. et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J. Clin. Oncol. 23, 741-750 (2005).
-
(2005)
J. Clin. Oncol.
, vol.23
, pp. 741-750
-
-
Sanderson, K.1
-
32
-
-
84944472689
-
Releasing the brakes on cancer immunotherapy
-
Ribas, A. Releasing the brakes on cancer immunotherapy. N. Engl. J. Med. 373, 1490-1492 (2015).
-
(2015)
N. Engl. J. Med.
, vol.373
, pp. 1490-1492
-
-
Ribas, A.1
-
33
-
-
84902825664
-
Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients
-
Cha, E. et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci. Transl. Med. 6, 238ra70 (2014).
-
(2014)
Sci. Transl. Med.
, vol.6
, pp. 238ra70
-
-
Cha, E.1
-
34
-
-
84884271914
-
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
-
Simpson, T. R. et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210, 1695-1710 (2013).
-
(2013)
J. Exp. Med.
, vol.210
, pp. 1695-1710
-
-
Simpson, T.R.1
-
35
-
-
85015873065
-
Immune toxicities elicited by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire
-
Oh, D. Y. et al. Immune toxicities elicited by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 77, 1322-1330 (2017).
-
(2017)
Cancer Res.
, vol.77
, pp. 1322-1330
-
-
Oh, D.Y.1
-
36
-
-
54449088740
-
Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade
-
Blackburn, S. D., Shin, H., Freeman, G. J. & Wherry, E. J. Selective expansion of a subset of exhausted CD8 T cells by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 105, 15016-15021 (2008).
-
(2008)
Proc. Natl. Acad. Sci. USA
, vol.105
, pp. 15016-15021
-
-
Blackburn, S.D.1
Shin, H.2
Freeman, G.J.3
Wherry, E.J.4
-
37
-
-
84999673353
-
Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells
-
De Simone, M. et al. Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells. Immunity 45, 1135-1147 (2016).
-
(2016)
Immunity
, vol.45
, pp. 1135-1147
-
-
De Simone, M.1
-
38
-
-
84994144982
-
Fulminant myocarditis with combination immune checkpoint blockade
-
Johnson, D. B. et al. Fulminant myocarditis with combination immune checkpoint blockade. N. Engl. J. Med. 375, 1749-1755 (2016).
-
(2016)
N. Engl. J. Med.
, vol.375
, pp. 1749-1755
-
-
Johnson, D.B.1
-
39
-
-
0036481263
-
Epitope spreading in immune-mediated diseases: Implications for immunotherapy
-
Vanderlugt, C. L. & Miller, S. D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2, 85-95 (2002).
-
(2002)
Nat. Rev. Immunol.
, vol.2
, pp. 85-95
-
-
Vanderlugt, C.L.1
Miller, S.D.2
-
40
-
-
0030848161
-
Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help
-
Bennett, S. R., Carbone, F. R., Karamalis, F., Miller, J. F. & Heath, W. R. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J. Exp. Med. 186, 65-70 (1997).
-
(1997)
J. Exp. Med.
, vol.186
, pp. 65-70
-
-
Bennett, S.R.1
Carbone, F.R.2
Karamalis, F.3
Miller, J.F.4
Heath, W.R.5
-
41
-
-
79951848084
-
Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases
-
Corbière, V. et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res. 71, 1253-1262 (2011).
-
(2011)
Cancer Res.
, vol.71
, pp. 1253-1262
-
-
Corbière, V.1
-
42
-
-
84993985148
-
T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression
-
Chapuis, A. G. et al. T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined With cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression. J. Clin. Oncol. 34, 3787-3795 (2016).
-
(2016)
J. Clin. Oncol.
, vol.34
, pp. 3787-3795
-
-
Chapuis, A.G.1
-
43
-
-
84996572349
-
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies
-
Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2, 112-120 (2014).
-
(2014)
Cancer Immunol. Res.
, vol.2
, pp. 112-120
-
-
Beatty, G.L.1
-
44
-
-
84866551703
-
Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients
-
Kwek, S. S. et al. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J. Immunol. 189, 3759-3766 (2012).
-
(2012)
J. Immunol.
, vol.189
, pp. 3759-3766
-
-
Kwek, S.S.1
-
45
-
-
84864332935
-
Cross-presentation by dendritic cells
-
Joffre, O. P., Segura, E., Savina, A. & Amigorena, S. Cross-presentation by dendritic cells. Nat. Rev. Immunol. 12, 557-569 (2012).
-
(2012)
Nat. Rev. Immunol.
, vol.12
, pp. 557-569
-
-
Joffre, O.P.1
Segura, E.2
Savina, A.3
Amigorena, S.4
-
46
-
-
34249799285
-
Cutting edge: Regulatory T cells induce CD4+CD25-Foxp3-T cells or are self-induced to become Th17 cells in the absence of exogenous TGF
-
Xu, L., Kitani, A., Fuss, I. & Strober, W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3-T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-. J. Immunol. 178, 6725-6729 (2007).
-
(2007)
J. Immunol.
, vol.178
, pp. 6725-6729
-
-
Xu, L.1
Kitani, A.2
Fuss, I.3
Strober, W.4
-
47
-
-
55149094300
-
Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells
-
Koenen, H. J. et al. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood 112, 2340-2352 (2008).
-
(2008)
Blood
, vol.112
, pp. 2340-2352
-
-
Koenen, H.J.1
-
48
-
-
80051801522
-
Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin
-
Bovenschen, H. J. et al. Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J. Invest. Dermatol. 131, 1853-1860 (2011).
-
(2011)
J. Invest. Dermatol.
, vol.131
, pp. 1853-1860
-
-
Bovenschen, H.J.1
-
49
-
-
84886242509
-
The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies
-
Muratori, L. & Longhi, M. S. The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies. J. Autoimmun. 46, 74-80 (2013).
-
(2013)
J. Autoimmun.
, vol.46
, pp. 74-80
-
-
Muratori, L.1
Longhi, M.S.2
-
50
-
-
84899749711
-
CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis
-
Zohar, Y. et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J. Clin. Invest. 124, 2009-2022 (2014).
-
(2014)
J. Clin. Invest.
, vol.124
, pp. 2009-2022
-
-
Zohar, Y.1
-
51
-
-
84922999148
-
The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation
-
DuPage, M. et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity 42, 227-238 (2015).
-
(2015)
Immunity
, vol.42
, pp. 227-238
-
-
DuPage, M.1
-
52
-
-
55949136562
-
Roles of the EZH2 histone methyltransferase in cancer epigenetics
-
Simon, J. A. & Lange, C. A. Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat. Res. 647, 21-29 (2008).
-
(2008)
Mutat. Res.
, vol.647
, pp. 21-29
-
-
Simon, J.A.1
Lange, C.A.2
-
53
-
-
84946912433
-
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
-
Peng, D. et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249-253 (2015).
-
(2015)
Nature
, vol.527
, pp. 249-253
-
-
Peng, D.1
-
54
-
-
85006761390
-
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
-
Lowe, J. R. et al. Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J. Immunother. Cancer 4, 89 (2016).
-
(2016)
J. Immunother. Cancer
, vol.4
, pp. 89
-
-
Lowe, J.R.1
-
55
-
-
84994852309
-
Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab
-
de Filette, J. et al. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J. Clin. Endocrinol. Metab. 101, 4431-4439 (2016).
-
(2016)
J. Clin. Endocrinol. Metab.
, vol.101
, pp. 4431-4439
-
-
De Filette, J.1
-
56
-
-
84964778827
-
-
Klocke, K., Sakaguchi, S., Holmdahl, R. & Wing, K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood 113, E2383-E2392 (2016).
-
(2016)
Induction of Autoimmune Disease by Deletion of CTLA-4 in Mice in Adulthood
, vol.113
, pp. E2383-E2392
-
-
Klocke, K.1
Sakaguchi, S.2
Holmdahl, R.3
Wing, K.4
-
57
-
-
2642655282
-
Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes
-
Lühder, F., Höglund, P., Allison, J. P., Benoist, C. & Mathis, D. Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes. J. Exp. Med. 187, 427-432 (1998).
-
(1998)
J. Exp. Med.
, vol.187
, pp. 427-432
-
-
Lühder, F.1
Höglund, P.2
Allison, J.P.3
Benoist, C.4
Mathis, D.5
-
58
-
-
57849168934
-
Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
-
Blackburn, S. D. et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10, 29-37 (2009).
-
(2009)
Nat. Immunol.
, vol.10
, pp. 29-37
-
-
Blackburn, S.D.1
-
59
-
-
84994364943
-
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade
-
Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160-1165 (2016).
-
(2016)
Science
, vol.354
, pp. 1160-1165
-
-
Pauken, K.E.1
-
60
-
-
34548680261
-
Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction
-
Kaufmann, D. E. et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8, 1246-1254 (2007).
-
(2007)
Nat. Immunol.
, vol.8
, pp. 1246-1254
-
-
Kaufmann, D.E.1
-
61
-
-
61449181280
-
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade
-
Nakamoto, N. et al. Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog. 5, e1000313 (2009).
-
(2009)
PLoS Pathog.
, vol.5
, pp. e1000313
-
-
Nakamoto, N.1
-
62
-
-
84994335422
-
The epigenetic landscape of T cell exhaustion
-
Sen, D. R. et al. The epigenetic landscape of T cell exhaustion. Science 354, 1165-1169 (2016).
-
(2016)
Science
, vol.354
, pp. 1165-1169
-
-
Sen, D.R.1
-
63
-
-
84940184252
-
Generation of knock-in primary human T cells using Cas9 ribonucleoproteins
-
Schumann, K. et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc. Natl. Acad. Sci. USA 112, 10437-10442 (2015).
-
(2015)
Proc. Natl. Acad. Sci. USA
, vol.112
, pp. 10437-10442
-
-
Schumann, K.1
-
64
-
-
85018387101
-
Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition
-
Ren, J. et al. Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition. Clin. Cancer Res. http://dx. doi. org/10. 1158/1078-0432. ccr-16-1300 (2016).
-
(2016)
Clin. Cancer Res.
-
-
Ren, J.1
-
65
-
-
84937846973
-
Evolving synergistic combinations of targeted immunotherapies to combat cancer
-
Melero, I. et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat. Rev. Cancer 15, 457-472 (2015).
-
(2015)
Nat. Rev. Cancer
, vol.15
, pp. 457-472
-
-
Melero, I.1
-
66
-
-
84936147067
-
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
-
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23-34 (2015).
-
(2015)
N. Engl. J. Med.
, vol.373
, pp. 23-34
-
-
Larkin, J.1
-
67
-
-
84875785905
-
Hepatotoxicity with combination of vemurafenib and ipilimumab
-
Ribas, A., Hodi, F. S., Callahan, M., Konto, C. & Wolchok, J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N. Engl. J. Med. 368, 1365-1366 (2013).
-
(2013)
N. Engl. J. Med.
, vol.368
, pp. 1365-1366
-
-
Ribas, A.1
Hodi, F.S.2
Callahan, M.3
Konto, C.4
Wolchok, J.5
-
68
-
-
84959133719
-
Combination cancer immunotherapies tailored to the tumour microenvironment
-
Smyth, M. J., Ngiow, S. F., Ribas, A. & Teng, M. W. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143-158 (2016).
-
(2016)
Nat. Rev. Clin. Oncol.
, vol.13
, pp. 143-158
-
-
Smyth, M.J.1
Ngiow, S.F.2
Ribas, A.3
Teng, M.W.4
-
69
-
-
84925326818
-
Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: A systematic review and meta-analysis
-
Teulings, H. E. et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J. Clin. Oncol. 33, 773-781 (2015).
-
(2015)
J. Clin. Oncol.
, vol.33
, pp. 773-781
-
-
Teulings, H.E.1
-
70
-
-
84864052441
-
Management of immune-related adverse events and kinetics of response with ipilimumab
-
Weber, J. S., Kähler, K. C. & Hauschild, A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30, 2691-2697 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 2691-2697
-
-
Weber, J.S.1
Kähler, K.C.2
Hauschild, A.3
-
71
-
-
84957565779
-
Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
-
Dubin, K. et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat. Commun. 7, 10391 (2016).
-
(2016)
Nat. Commun.
, vol.7
, pp. 10391
-
-
Dubin, K.1
-
72
-
-
84919964373
-
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies
-
Liu, J., Blake, S. J., Smyth, M. J. & Teng, M. W. Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin. Transl. Immunology 3, e22 (2014).
-
(2014)
Clin. Transl. Immunology
, vol.3
, pp. e22
-
-
Liu, J.1
Blake, S.J.2
Smyth, M.J.3
Teng, M.W.4
-
73
-
-
36849010167
-
Adaptive immunity maintains occult cancer in an equilibrium state
-
Koebel, C. M. et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 450, 903-907 (2007).
-
(2007)
Nature
, vol.450
, pp. 903-907
-
-
Koebel, C.M.1
-
74
-
-
0037421593
-
Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery
-
MacKie, R. M., Reid, R. & Junor, B. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N. Engl. J. Med. 348, 567-568 (2003).
-
(2003)
N. Engl. J. Med.
, vol.348
, pp. 567-568
-
-
MacKie, R.M.1
Reid, R.2
Junor, B.3
-
75
-
-
80455162464
-
Inducible apoptosis as a safety switch for adoptive cell therapy
-
Di Stasi, A. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673-1683 (2011).
-
(2011)
N. Engl. J. Med.
, vol.365
, pp. 1673-1683
-
-
Di Stasi, A.1
-
76
-
-
84885783438
-
Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy
-
Bouchlaka, M. N. et al. Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J. Exp. Med. 210, 2223-2237 (2013).
-
(2013)
J. Exp. Med.
, vol.210
, pp. 2223-2237
-
-
Bouchlaka, M.N.1
-
77
-
-
84911904714
-
Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice
-
Mirsoian, A. et al. Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J. Exp. Med. 211, 2373-2383 (2014).
-
(2014)
J. Exp. Med.
, vol.211
, pp. 2373-2383
-
-
Mirsoian, A.1
-
78
-
-
34447514029
-
Vitamin D deficiency
-
Holick, M. F. Vitamin D deficiency. N. Engl. J. Med. 357, 266-281 (2007).
-
(2007)
N. Engl. J. Med.
, vol.357
, pp. 266-281
-
-
Holick, M.F.1
-
79
-
-
84940894814
-
Increased incidence of chronic GvHD and CMV disease in patients with Vitamin D deficiency before allogeneic stem cell transplantation
-
von Bahr, L. et al. Increased incidence of chronic GvHD and CMV disease in patients with vitamin D deficiency before allogeneic stem cell transplantation. Bone Marrow Transplant. 50, 1217-1223 (2015).
-
(2015)
Bone Marrow Transplant.
, vol.50
, pp. 1217-1223
-
-
Von Bahr, L.1
-
80
-
-
70449368149
-
Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: Differential role for PD-L1
-
Unger, W. W., Laban, S., Kleijwegt, F. S., van der Slik, A. R. & Roep, B. O. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur. J. Immunol. 39, 3147-3159 (2009).
-
(2009)
Eur. J. Immunol.
, vol.39
, pp. 3147-3159
-
-
Unger, W.W.1
Laban, S.2
Kleijwegt, F.S.3
Van Der Slik, A.R.4
Roep, B.O.5
-
81
-
-
48749085956
-
Control of autoimmune diseases by the Vitamin D endocrine system
-
Adorini, L. & Penna, G. Control of autoimmune diseases by the vitamin D endocrine system. Nat. Clin. Pract. Rheumatol. 4, 404-412 (2008).
-
(2008)
Nat. Clin. Pract. Rheumatol.
, vol.4
, pp. 404-412
-
-
Adorini, L.1
Penna, G.2
-
82
-
-
84933037300
-
Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients with systemic lupus erythematosus
-
Aranow, C. et al. Randomized, double-blind, placebo-controlled trial of the effect of vitamin D3 on the interferon signature in patients With systemic lupus erythematosus. Arthritis Rheumatol. 67, 1848-1857 (2015).
-
(2015)
Arthritis Rheumatol.
, vol.67
, pp. 1848-1857
-
-
Aranow, C.1
-
83
-
-
84948461699
-
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
-
Vétizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079-1084 (2015).
-
(2015)
Science
, vol.350
, pp. 1079-1084
-
-
Vétizou, M.1
-
84
-
-
84948451779
-
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
-
Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084-1089 (2015).
-
(2015)
Science
, vol.350
, pp. 1084-1089
-
-
Sivan, A.1
-
85
-
-
84978431877
-
The microbiota in adaptive immune homeostasis and disease
-
Honda, K. & Littman, D. R. The microbiota in adaptive immune homeostasis and disease. Nature 535, 75-84 (2016).
-
(2016)
Nature
, vol.535
, pp. 75-84
-
-
Honda, K.1
Littman, D.R.2
-
86
-
-
84992074418
-
Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut
-
Kakihana, K. et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood 128, 2083-2088 (2016).
-
(2016)
Blood
, vol.128
, pp. 2083-2088
-
-
Kakihana, K.1
-
87
-
-
84857815877
-
Immunologic correlates of the abscopal effect in a patient with melanoma
-
Postow, M. A. et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 366, 925-931 (2012).
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 925-931
-
-
Postow, M.A.1
-
88
-
-
84957928309
-
The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer
-
Ward, J. P., Gubin, M. M. & Schreiber, R. D. The role of neoantigens in naturally occurring and therapeutically induced immune responses to cancer. Adv. Immunol. 130, 25-74 (2016).
-
(2016)
Adv. Immunol.
, vol.130
, pp. 25-74
-
-
Ward, J.P.1
Gubin, M.M.2
Schreiber, R.D.3
-
89
-
-
85006355534
-
Recent advances in immunotherapy in metastatic NSCLC
-
Bansal, P., Osman, D., Gan, G. N., Simon, G. R. & Boumber, Y. Recent advances in immunotherapy in metastatic NSCLC. Front. Oncol. 6, 239 (2016).
-
(2016)
Front. Oncol.
, vol.6
, pp. 239
-
-
Bansal, P.1
Osman, D.2
Gan, G.N.3
Simon, G.R.4
Boumber, Y.5
-
90
-
-
84983535198
-
Moving programmed death-1 inhibitors to the front lines in non-small-cell lung cancer
-
Gainor, J. F. Moving programmed death-1 inhibitors to the front lines in non-small-cell lung cancer. J. Clin. Oncol. 34, 2953-2955 (2016).
-
(2016)
J. Clin. Oncol.
, vol.34
, pp. 2953-2955
-
-
Gainor, J.F.1
-
91
-
-
0031240055
-
Epidemiology and estimated population burden of selected autoimmune diseases in the United States
-
Jacobson, D. L., Gange, S. J., Rose, N. R. & Graham, N. M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84, 223-243 (1997).
-
(1997)
Clin. Immunol. Immunopathol.
, vol.84
, pp. 223-243
-
-
Jacobson, D.L.1
Gange, S.J.2
Rose, N.R.3
Graham, N.M.4
-
92
-
-
70149114880
-
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
-
Johnson, L. A. et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114, 535-546 (2009).
-
(2009)
Blood
, vol.114
, pp. 535-546
-
-
Johnson, L.A.1
-
93
-
-
84876859096
-
T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy
-
Zhong, S. et al. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc. Natl. Acad. Sci. USA 110, 6973-6978 (2013).
-
(2013)
Proc. Natl. Acad. Sci. USA
, vol.110
, pp. 6973-6978
-
-
Zhong, S.1
-
94
-
-
77952236875
-
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy
-
1p, 570
-
Bendle, G. M. et al. Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat. Med. 16, 565-570, 1p, 570 (2010).
-
(2010)
Nat. Med.
, vol.16
, pp. 565-570
-
-
Bendle, G.M.1
-
95
-
-
85011955241
-
Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
-
Teachey, D. T. et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6, 664-679 (2016).
-
(2016)
Cancer Discov.
, vol.6
, pp. 664-679
-
-
Teachey, D.T.1
-
96
-
-
84940720703
-
Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor
-
van den Berg, J. H. et al. Case report of a fatal serious adverse event upon administration of T cells transduced with a MART-1-specific T-cell receptor. Mol. Ther. 23, 1541-1550 (2015).
-
(2015)
Mol. Ther.
, vol.23
, pp. 1541-1550
-
-
Van Den Berg, J.H.1
-
97
-
-
84963594644
-
Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease
-
Brudno, J. N. et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112-1121 (2016).
-
(2016)
J. Clin. Oncol.
, vol.34
, pp. 1112-1121
-
-
Brudno, J.N.1
-
98
-
-
84890827981
-
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
-
Kochenderfer, J. N. et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood 122, 4129-4139 (2013).
-
(2013)
Blood
, vol.122
, pp. 4129-4139
-
-
Kochenderfer, J.N.1
-
99
-
-
85008600121
-
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
-
Ghosh, A. et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat. Med. 23, 242-249 (2017).
-
(2017)
Nat. Med.
, vol.23
, pp. 242-249
-
-
Ghosh, A.1
-
100
-
-
84860681545
-
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer
-
Provasi, E. et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat. Med. 18, 807-815 (2012).
-
(2012)
Nat. Med.
, vol.18
, pp. 807-815
-
-
Provasi, E.1
-
101
-
-
84960393099
-
Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
-
Osborn, M. J. et al. Evaluation of TCR gene editing achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases. Mol. Ther. 24, 570-581 (2016).
-
(2016)
Mol. Ther.
, vol.24
, pp. 570-581
-
-
Osborn, M.J.1
-
102
-
-
84987784957
-
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
-
Cherkassky, L. et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126, 3130-3144 (2016).
-
(2016)
J. Clin. Invest.
, vol.126
, pp. 3130-3144
-
-
Cherkassky, L.1
-
103
-
-
84872196489
-
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells
-
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71-75 (2013).
-
(2013)
Nat. Biotechnol.
, vol.31
, pp. 71-75
-
-
Kloss, C.C.1
Condomines, M.2
Cartellieri, M.3
Bachmann, M.4
Sadelain, M.5
-
104
-
-
84945217637
-
Remote control of therapeutic T cells through a small molecule-gated chimeric receptor
-
Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J. & Lim, W. A. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350, aab4077 (2015).
-
(2015)
Science
, vol.350
, pp. aab4077
-
-
Wu, C.Y.1
Roybal, K.T.2
Puchner, E.M.3
Onuffer, J.4
Lim, W.A.5
-
105
-
-
84990855364
-
Engineering T cells with customized therapeutic response programs using synthetic notch receptors
-
e16
-
Roybal, K. T. et al. Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 167, 419-432. e16 (2016).
-
(2016)
Cell
, vol.167
, pp. 419-432
-
-
Roybal, K.T.1
|